Cargando…

Safety and Efficacy of Concurrent or Sequential Radiotherapy Plus (PD-1) Inhibitors in Oligometastatic Esophageal Cancer

PURPOSE: We assess real-world outcomes, including safety and efficacy, of concurrent or sequential treatment with radiotherapy plus programmed cell death protein 1 (PD-1) inhibitors in patients with oligometastatic esophageal cancer (OMEC). METHODS: This cohort study retrospectively collected clinic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duan, Yanan, Qin, Wenru, Yang, Linlin, Zou, Bing, Qie, Wenting, Song, Ruiting, Xue, Lu, Wang, Linlin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9849787/ https://www.ncbi.nlm.nih.gov/pubmed/36685716 http://dx.doi.org/10.2147/CMAR.S391529

Ejemplares similares

Association between immune-related adverse events and the efficacy of PD-1 inhibitors in advanced esophageal cancer
por: Qin, Wenru, et al.
Publicado: (2022)

Incidence of pneumonitis following the use of different anaplastic lymphoma kinase tyrosine kinase inhibitor regimens: An updated systematic review and meta‐analysis
por: Qie, Wenting, et al.
Publicado: (2023)

Radiotherapy Plus Concurrent or Sequential Temozolomide for Glioblastoma in the Elderly: A Meta-Analysis
por: Yin, An-an, et al.
Publicado: (2013)

Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer
por: Wang, Peiliang, et al.
Publicado: (2021)

Correction to: Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer
por: Wang, Peiliang, et al.
Publicado: (2021)

Evaluation of Concurrent Chemoradiotherapy for Survival Outcomes in Patients With Synchronous Oligometastatic Esophageal Squamous Cell Carcinoma
por: Shi, Zhenguo, et al.
Publicado: (2022)

Radiotherapy for Oligometastatic Lung Cancer
por: Bergsma, Derek P., et al.
Publicado: (2017)

Toxicity Profile of Combining PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy in Non-Small Cell Lung Cancer: A Systematic Review
por: Li, Butuo, et al.
Publicado: (2021)

Efficacy and Safety of Local Radiotherapy to All Oligometastatic Sites in Elderly Patients with Metachronous Oligometastatic Cancers After Initial Treatment for the Primary Tumor
por: Hu, Xiaolong, et al.
Publicado: (2021)

Apatinib plus Radiotherapy on the Expression of CEA and VEGF in Advanced Oligometastatic Non-Small-Cell Lung Cancer
por: Zhu, Yanxing, et al.
Publicado: (2023)

Long-term survival after sequential local treatments for oligometastatic esophageal squamous cell carcinoma: A case report
por: Kroese, Tiuri E., et al.
Publicado: (2022)

Stereotactic Ablative Radiotherapy for Oligometastatic Disease in Liver
por: Kim, Myungsoo, et al.
Publicado: (2014)

Stereotactic ablative radiotherapy for oligometastatic prostate cancer
por: Gallizia, Elena, et al.
Publicado: (2022)

Long-term results of paclitaxel plus cisplatin with concurrent radiotherapy for loco-regional esophageal squamous cell carcinoma
por: Zhu, Han-Ting, et al.
Publicado: (2017)

Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature
por: Watanabe, Tsubasa, et al.
Publicado: (2020)

S-1 plus cisplatin with concurrent radiotherapy for stage III non-small cell lung cancer: A meta-analysis (PRISMA) of randomized control trials
por: Qie, Shuai, et al.
Publicado: (2018)

Radiotherapy of oligometastatic prostate cancer: a systematic review
por: Rogowski, Paul, et al.
Publicado: (2021)

Role of radiotherapy in oligometastatic breast cancer: Review of the literature
por: Beduk Esen, Caglayan Selenge, et al.
Publicado: (2022)

Efficacy and safety of weekly nab-paclitaxel plus cisplatin with concurrent intensity-modulated radiotherapy in patients with inoperable, locally advanced esophageal cancer: a pilot trial
por: Wang, Daquan, et al.
Publicado: (2018)

Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma
por: Zhang, Wencheng, et al.
Publicado: (2021)

Prophylactic cranial irradiation-related lymphopenia affects survival in patients with limited-stage small cell lung cancer
por: Fan, Xinyu, et al.
Publicado: (2023)

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence
por: Decaestecker, Karel, et al.
Publicado: (2014)

Role of Radiosurgery/Stereotactic Radiotherapy in Oligometastatic Disease: Brain Oligometastases
por: Mazzola, Rosario, et al.
Publicado: (2019)

Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Spine Metastases: An Overview
por: Zeng, Kang Liang, et al.
Publicado: (2019)

Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer
por: Weykamp, Fabian, et al.
Publicado: (2020)

Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer
por: Patel, Priyanka H., et al.
Publicado: (2019)

Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer
por: Katano, Atsuto, et al.
Publicado: (2021)

Proton Radiotherapy for Patients With Oligometastatic Breast Cancer Involving the Sternum
por: Johnson, Andrew, et al.
Publicado: (2021)

Stereotactic ablative radiotherapy for oligometastatic breast cancer in elderly patients
por: Morales-Orue, Ignacio, et al.
Publicado: (2020)

Radiotherapy is the Preferred Primary Tumor Treatment in Oligometastatic Prostate Cancer
por: van Moorselaar, R. Jeroen A., et al.
Publicado: (2022)

Stereotactic body radiotherapy for recurrent and oligometastatic soft tissue sarcoma
por: Feng, Xiao-Yao, et al.
Publicado: (2022)

Comparison of the Incidence Rate of Radiation Pneumonitis Observed in Patients with Advanced Lung Adenocarcinoma Treated with Simultaneous Thoracic Radiotherapy and 1G/2G/3G EGFR-TKIs
por: Mu, Fengchun, et al.
Publicado: (2023)

Addition of Induction or Consolidation Chemotherapy in Definitive Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone for Patients With Unresectable Esophageal Cancer: A Systematic Review and Meta-Analysis
por: Wang, Jianing, et al.
Publicado: (2021)

Concurrent use of nivolumab and radiotherapy for patients with metastatic non-small cell lung cancer and renal cell carcinoma with oligometastatic disease progression on nivolumab
por: Ansari, Jawaher, et al.
Publicado: (2021)

Efficacy and safety of anti-PD-1 antibody plus chemoradiotherapy in locally advanced esophageal squamous cancer
por: Ma, Ji, et al.
Publicado: (2023)

Hypofractionated radiotherapy for primary or secondary oligometastatic lung cancer using Tomotherapy
por: Chang, Heng-Jui, et al.
Publicado: (2012)

Local ablative radiotherapy for oligometastatic non-small cell lung cancer
por: Suh, Yang-Gun, et al.
Publicado: (2019)

CyberKnife Stereotactic Ablative Radiotherapy for Recurrent or Oligometastatic Gynecological Cancers
por: Kataria, Tejinder, et al.
Publicado: (2021)

Stereotactic Radiotherapy in the Treatment of Paraneoplastic Vasculitis in Oligometastatic Renal Cell Carcinoma
por: Burgess, Laura, et al.
Publicado: (2021)

Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review
por: Yaney, Alexander, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n1etfohmu4ofvv95omujjdnen9